Development of RSV vaccines: where are we?

N. Scheltema (Utrecht, Netherlands)

Source: International Congress 2019 – Respiratory syncytial virus infections throughout life
Session: Respiratory syncytial virus infections throughout life
Session type: Symposium
Number: 5311
Disease area: -

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Scheltema (Utrecht, Netherlands). Development of RSV vaccines: where are we?. International Congress 2019 – Respiratory syncytial virus infections throughout life

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Development of RSV antiviral treatment: where are we?
Source: International Congress 2019 – Respiratory syncytial virus infections throughout life
Year: 2019


Seasonal influenza vaccine effectiveness in people with asthma: A systematic review
Source: International Congress 2016 – Clinical studies in asthma and immunology
Year: 2016

New treatments for RSV and other viruses, including update on vaccines
Source: ERS Courses: Paediatric respiratory infections
Year: 2019


Understanding new vaccines for SARS-CoV-2 and their regulation
Source: ERS webinar 2021: Understanding new vaccines for SARS-CoV-2 and their regulation
Year: 2021


Ebola: progress with vaccines
Source: International Congress 2015 – Pandemics and emerging infections
Year: 2015



Influenza surveillance and vaccination: new developments
Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice
Year: 2017


COVID-19 vaccination and more
Source: ERS webinar 2021: COVID-19 vaccination and more
Year: 2021


Novel intradermal influenza vaccine: phase 3 data in targeted adult populations
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Immunology underpinning vaccine strategy: what is the risk of reinfection?
Source: Virtual Congress 2020 – Management prevention
Year: 2020


Pneumococcal vaccine: when, what, how and to whom
Source: International Congress 2014 – MS06 What's new in pneumococcal vaccination?
Year: 2014


COVID-19 mRNA vaccines: a step forward from traditional vaccines?
Source: Virtual Congress 2021 – Scientific year in review
Year: 2021


Medical staff attitude to vaccination against an influenza virus
Source: Annual Congress 2013 –Epidemiology of respiratory disease
Year: 2013

Should pneumococcal vaccines be used to prevent LRTI?
Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new?
Year: 2009

Rhinovirus vaccination: the case in favour
Source: Eur Respir J 2011; 37: 3-4
Year: 2011


Influenza: vaccination and treatment
Source: Eur Respir J 2001; 17: 1282-1293
Year: 2001



Pandemic influenza: using evidence on vaccines and antivirals for clinical decisions and policy making
Source: Eur Respir J 2006; 27: 661-663
Year: 2006